Tompkins Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tompkins Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.02K	Hold	25	–	–	﹤0.01%	488
2026 Q1	$4.73K	Hold	25	–	–	﹤0.01%	497
2025 Q4	$4.25K	Hold	25	–	–	﹤0.01%	495
2025 Q3	$3.29K	Hold	25	–	–	﹤0.01%	494
2025 Q2	$2.65K	Hold	25	–	–	﹤0.01%	499
2025 Q1	$3.1K	Sell	25 -25	-50%	-$3.26K	﹤0.01%	511
2024 Q4	$6.16K	Hold	50	–	–	﹤0.01%	455
2024 Q3	$5.57K	Sell	50 -100	-67%	-$11K	﹤0.01%	509
2024 Q2	$16K	Buy	+150	New	+$16.5K	﹤0.01%	452
2021 Q1	–	Sell	-5	Closed	-$1K	–	472
2020 Q4	$1K	Buy	+5	New	+$745	﹤0.01%	465

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Tompkins Financial's JAZZ Position: Q2 2026 in Review

Tompkins Financial held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 25 shares worth $6.02K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

Tompkins Financial first reported a position in JAZZ in Q4 2020 and has held it in 10 quarters since. The position peaked at $16K in Q2 2024. 87 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Tompkins Financial held 25 shares of Jazz Pharmaceuticals worth $6.02K as of Q2 2026.
Tompkins Financial left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Tompkins Financial's portfolio in Q2 2026, its #488 holding.
Tompkins Financial first reported a position in Jazz Pharmaceuticals in Q4 2020 and has held it in 10 quarters since.
Tompkins Financial's Jazz Pharmaceuticals position peaked at $16K in Q2 2024.
87 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Tompkins Financial's 13F filing for Q2 2026, filed 15 Jul 2026.